Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 35Other hematologic neoplasm 7Sarcoma 2Plasma cell 2Classical hematology 1CNS 1

Conditions

Central Nervous System Neoplasms 6Neuroblastoma 4Testicular Neoplasms 3Testicular Germ Cell Tumor 3Brain Neoplasms 3Seminoma 2Pheochromocytoma 2Ovarian Neoplasms 2Medulloblastoma 2Glioma 2Endodermal Sinus Tumor 2Thrombocytopenia 1Teratoma 1Microphthalmia, Isolated, with Coloboma 5 1Lymphoma 1Intraocular Lymphoma 1Gliosarcoma 1Glioblastoma 1Dysgerminoma 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma, Embryonal 1

Interventions

Filgrastim 11Temozolomide 9Melphalan 9Cyclophosphamide 9Radiotherapy 7Busulfan 7Magnetic Resonance Spectroscopy 6Rituximab 5Psychiatric Rehabilitation 5Methotrexate 5Etoposide 5Cytarabine 5Carboplatin 5sargramostim 4fludarabine 4etoposide phosphate 4Thiotepa 4Nivolumab 4Methylprednisolone 4Flow Cytometry 4Alemtuzumab 4Vincristine 3Topotecan 3Specimen Handling 3Peripheral Blood Stem Cell Transplantation 3Pemetrexed 3Granulocyte Colony-Stimulating Factor 3Early Intervention, Educational 3Drug Therapy 3Dexamethasone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × pegfilgrastim × CNS × Clear all
NCT00074165 2023-07-06

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

OHSU Knight Cancer Institute

Phase 2 Terminated
17 enrolled 7 charts
CNSClassical hematologyLymphoid

Lymphoma, Thrombocytopenia, Central Nervous System Neoplasms, Intraocular Lymphoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡